Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma

Paolo A Ascierto,Mario Mandalà,Pier Francesco Ferrucci,Massimo Guidoboni,Piotr Rutkowski,Virginia Ferraresi,Ana Arance,Michele Guida,Evaristo Maiello,Helen Gogas,Erika Richtig,Pietro Quaglino,Céleste Lebbé,Hildur Helgadottir,Paola Queirolo,Francesco Spagnolo,Marco Tucci,Michele Del Vecchio,Maria Gonzalez-Cao,Alessandro Marco Minisini,Sabino De Placido,Miguel F Sanmamed,Milena Casula,Jenny Bulgarelli,Marina Pisano,Claudia Piccinini,Luisa Piccin,Antonio Cossu,Domenico Mallardo,Miriam Paone,Maria Grazia Vitale,Ignacio Melero,Antonio M Grimaldi,Diana Giannarelli,Giuseppe Palmieri,Reinhard Dummer,Vanna Chiarion Sileni

DOI: https://doi.org/10.1056/EVIDoa2400087

Abstract:Background: The impact of the order of treatment with checkpoint inhibitors or BRAF/MEK inhibitors on the development of brain metastases in patients with metastatic unresectable BRAFV600-mutant melanoma is unknown. The SECOMBIT trial examined the impact of the order of receipt of these treatments in such patients. Methods: In this three-arm trial, we reviewed patients without brain metastases who received the BRAF/MEK inhibitors encorafenib and binimetinib until they had progressive disease followed by the immune checkpoint inhibitors ipilimumab and nivolumab (arm A); or treatment with ipilimumab and nivolumab until they had progressive disease followed by encorafenib and binimetinib (arm B); or treatment with encorafenib and binimetinib for 8 weeks followed by ipilimumab and nivolumab until they had progressive disease followed by retreatment with encorafenib arm binimetinib (arm C). Results: Brain metastases were discovered during the trial in 23/69 patients in arm A, 11/69 in arm B, and 9/68 in arm C. At a median follow-up of 56 months, the 60-month brain metastases-free survival rates were 56% for arm A, 80% for arm B (hazard ratio [HR] vs. A: 0.40, 95% confidence interval [CI] 0.23 to 0.58), and 85% for arm C (HR vs. A: 0.35, 95% CI 0.16 to 0.76). Conclusions: In patients with unresectable metastatic melanoma, the treatment sequence of immune checkpoint inhibition followed by BRAF/MEK inhibitors was associated with longer periods of new brain metastases-free survival than the reverse sequence. A regimen in which immune checkpoint inhibition was sandwiched between BRAF/MEK inhibition also appeared to be protective against brain metastases. (ClinicalTrials.gov number NCT02631447.).